Not a good buy right now for an impatient buyer: the chart is in a clear downtrend (bearish MAs + weakening MACD), and similar-pattern stats skew negative over the next month.
Oversold conditions (RSI near 26) can produce short bounces, but there is no proprietary buy signal today to justify chasing a rebound.
Insider buying is a positive, but fundamentals remain weak (no revenue, widening losses YoY), so the risk/reward is unfavorable right now.
Momentum: MACD histogram is negative (-0.0637) and negatively expanding, implying selling pressure is still increasing.
RSI: RSI_6 at 26.54 suggests the stock is oversold (bounce potential), but oversold can persist in downtrends.
Key levels:
Support: S1 3.119 (very near current 3.15), then S2 2.895.
Resistance: Pivot 3.482, then R1 3.845.
Pattern-based expectation: ~40% chance of small upside next day/week (+0.63% / +1.76%), but the next-month expectation is negative (-8.75%), aligning with the bearish trend.
Reported put/call ratios are 0.0 for both open interest and volume, which likely indicates extremely limited options activity and/or missing feeds—so options sentiment is not reliable here.
No meaningful IV/volume trend metrics provided (most fields blank), limiting the ability to confirm bullish/bearish positioning via derivatives.
Technical Summary
Sell
8
Buy
6
Positive Catalysts
increases odds of a short-term reflex bounce if support holds near 3.
Hedge funds are neutral (no notable recent selling pressure from that cohort indicated).
Neutral/Negative Catalysts
No recent news in the past week: no visible near-term catalyst to reverse the prevailing downtrend.
Strongly bearish technical structure (MA stack + MACD deterioration) suggests rallies may be sold.
Similar-pattern forward stats point to downside over the next month (-8.75%).
Financial deterioration (larger losses YoY) keeps funding/dilution risk elevated for a development-stage biotech.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY change) — still pre/near-commercial with no top-line traction.
Net income: -4,443,877 (down -69.70% YoY) — losses widened.
Gross margin: 0 (0.00% YoY) — consistent with zero revenue.
Overall: growth trend remains unfavorable (no revenue + widening losses), which weakens the case for buying without a clear catalyst or confirmed technical reversal.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so a clear Wall Street consensus trend cannot be confirmed.
Practical “pros” view (if any): insider accumulation can be interpreted as internal confidence.
Practical “cons” view: absent revenue and worsening losses typically keep professional sentiment cautious until clinical/financing catalysts emerge.
Politicians / influential-figure activity: No recent congress trading data available (and no other political trading signals provided).
Wall Street analysts forecast CLRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CLRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 2.820
Low
0
Averages
0
High
0
0
Current: 2.820
Low
0
Averages
0
High
0
Roth Capital
Buy
maintain
$3 -> $18
AI Analysis
2025-08-14
Reason
Roth Capital
Price Target
$3 -> $18
AI Analysis
2025-08-14
maintain
Buy
Reason
Roth Capital adjusted the firm's price target on Cellectar Biosciences to $18 from $3 and keeps a Buy rating on the shares post the Q2 report. The new price target largely reflects the company's reverse split.
Maxim
Buy
to
Hold
downgrade
2025-05-14
Reason
Maxim
Price Target
2025-05-14
downgrade
Buy
to
Hold
Reason
Maxim downgraded Cellectar Biosciences to Hold from Buy. Cellectar's radiopharma pipeline, including the Phase 1-ready assets CLR-121225 and CLR-121125, were the key drivers for Cellectar, but as the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLRB
